14,940 reports of this reaction
2.2% of all TOCILIZUMAB reports
#7 most reported adverse reaction
FATIGUE is the #7 most commonly reported adverse reaction for TOCILIZUMAB, manufactured by Genentech, Inc.. There are 14,940 FDA adverse event reports linking TOCILIZUMAB to FATIGUE. This represents approximately 2.2% of all 689,384 adverse event reports for this drug.
TOCILIZUMAB has an overall safety score of 85 out of 100. Patients taking TOCILIZUMAB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for TOCILIZUMAB, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for TOCILIZUMAB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 14,940 FDA reports for TOCILIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.2% of all adverse event reports for TOCILIZUMAB, making it a notable side effect.
If you experience fatigue while taking TOCILIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.